Sangamo Therapeutics Inc (SGMO) concluded trading on Wednesday at a closing price of $0.87, with 4.81 million shares of worth about $4.19 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 3.17% during that period and on March 05, 2025 the price saw a gain of about 1.77%. Currently the company’s common shares owned by public are about 208.62M shares, out of which, 199.25M shares are available for trading.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 0 times over the past 12 months. They bought 0 shares in 0 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
Stock saw a price change of -10.63% in past 5 days and over the past one month there was a price change of -25.22%. Year-to-date (YTD), SGMO shares are showing a performance of -14.23% which decreased to -21.18% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.30 but also hit the highest price of $3.18 during that period. The average intraday trading volume for Sangamo Therapeutics Inc shares is 6.49 million. The stock is currently trading -18.45% below its 20-day simple moving average (SMA20), while that difference is down -33.21% for SMA50 and it goes to -23.03% lower than SMA200.
Sangamo Therapeutics Inc (NASDAQ: SGMO) currently have 208.62M outstanding shares and institutions hold larger chunk of about 29.73% of that.
The stock has a current market capitalization of $182.54M and its 3Y-monthly beta is at 1.47. It has posted earnings per share of -$0.74 in the same period. It has Quick Ratio of 1.35 while making debt-to-equity ratio of 0.71. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SGMO, volatility over the week remained 13.28% while standing at 9.39% over the month.
Stock’s fiscal year EPS is expected to rise by 68.13% while it is estimated to increase by 51.24% in next year. EPS is likely to grow at an annualized rate of 39.84% for next 5-years, compared to annual growth of -15.96% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Truist on December 13, 2024 offering a Buy rating for the stock and assigned a target price of $7 to it. Coverage by H.C. Wainwright stated Sangamo Therapeutics Inc (SGMO) stock as a Buy in their note to investors on December 10, 2024, suggesting a price target of $10 for the stock. On November 03, 2023, RBC Capital Mkts Downgrade their recommendations, while on April 28, 2023, BofA Securities Downgrade their ratings for the stock with a price target of $1.50. Stock get an Outperform rating from Wedbush on February 27, 2023.
